33 results about "Glucosylceramides" patented technology

The present invention provides amino ceramide-like compounds which inhibit glucosyl ceramide (GlyCer) formation by inhibiting the enzyme GlyCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore useful in therapeutic methods for treating various conditions and diseases associated with altered glycosphingolipid levels.

Novel amino ceramide-like compounds (1) are provided which inhibit glucosyl ceramide (GlcCer) formation by inhibiting the enzyme GlcCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore highly useful in therapeutic methods for treating various conditions and diseases associated with altered glycosphingolipid levels.

This invention pertains to pharmaceutical formulations which comprise (i) a drug (e.g., an amphiphilic drug) (e.g., an anthracycline) (e.g., doxorubicin) and (ii) a short-chain sphingolipid (e.g., a short-chain glycosphingolipid or a short-chain sphingomyelin) (e.g., N-octanoyl-glucosylceramide, referred to as C8-GlcCer) (e.g., N-hexanoyl-sphingomyelin, referred to herein as C6-SM), and which provide improved drug delivery and efficacy. The short-chain sphingolipidis selected from compounds of the following formula: wherein: R1 is independently: an O-linked saccharide group; or an O-linked polyhydric alcohol group; or: R1 is independently: an O-linked (optionally N-(C1-4alkyl)-substituted amino)-C1-6alkyl-phosphate group; or an O-linked (polyhydric alcohol-substituted)-C1-6alkyl-phosphate group; R2 is independently C3-9alkyl, and is independently unsubstituted or substituted; R3 is independently C7-19alkyl, and is independently unsubstituted or substituted; R4 is independently —H, —OH, or —O—C1-4alkyl; RN is independently —H or C1-4alkyl; the bond marked with an alpha (α) is independently a single bond or a double bond; if the bond marked with an alpha (α) is a double bond, then R5 is —H; if the bond marked with an alpha (α) is a single bond, then R5 is —H or —OH; the carbon atom marked (*) is independently in an R-configuration or an S-configuration; the carbon atom marked (**) is independently in an R-configuration or an S-configuration; and pharmaceutically acceptable salts, solvates, esters, ethers, chemically protected forms thereof. In one embodiment, the pharmaceutical formulation is a liposomal pharmaceutical formulation prepared using a mixture of lipids comprising, at least, vesicle-forming lipids (e.g., phospholipids) (e.g., phosphatidylcholines) (e.g., fully hydrogenated soy phosphatidylcholine (HSPC)) (e.g., dipalmitoyl-phosphatidylcholine (DPPC)) and said short-chain sphingolipid, and optionally cholesterol and optionally a vesicle-forming lipid which is derivatized with a polymer chain (e.g., a phosphatidylethanolamine (PE) which is derivatized with polyethyleneglycol (PEG)) (e.g., N-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine sodium salt (MPEG2000-DSPE). The present invention also pertains to methods for the preparation and use of such formulations.

The invention relates to the use of β-glycolipids as immunomodulators. More particularly, the invention relates to the use of β-glycolipids, preferably, β-lactosyl-ceramide, β-glucosylceramide, β-galactosyl-ceramide, ceramid and β-lactosyl-ceramide, as well as any mixture or combination thereof for the treatment of immune related disorders. The present invention further relates to a process for the modulation of the Th1 / Th2 cell balance toward anti-inflammatory cytokine producing cells, in a subject suffering from an immune related disorder. Therapeutic compositions and method for the preparation of these compositions are also provided.

The invention relates to a method for preparing D-glucosylceramide by using a soy sauce filter residue, and is characterized in that the method comprises the following steps: activating strains: A, respectively inoculating 100 mL of an activation culture medium with an sphingomonas strain and a yarrowia lipolytica strain; B, carrying out aerobic fermentation culture of the sphingomonas strain activated culture liquid P and the yarrowia lipolytica strain activated culture liquid Q obtained in the step A for 36-72 h, to obtain a composite strain fermentation liquid; C, mixing the composite strain fermentation liquid with the soy sauce filter residue, adding the mixture into a compound fermentation tank, carrying out static culture, and culturing for 48-96 h at the temperature of 25-30 DEG C, to obtain a strain cell-rich filter residue; and carrying out high pressure homogenization for 2 times, to obtain a wall-broken cell homogenate; and D, mixing the wall-broken cell homogenate with an ethanol solution, filtering to obtain a precipitate, and thus obtaining a D-glucosylceramide extract. Through rational use of the soy sauce filter residue, the waste can be turned into treasure, soy sauce industries are facilitated to improve economic benefits, and the resource utilization of the soy sauce filter residue and the development of high-value by-products are greatly improved.

The present invention relates to a combination therapy for the treatment of immune-related disorders. More particularly, the invention relates to oral or mucosal synergistic compositions combining beta-glycolipids, preferably, β-glycosphin-golipids with immunoglobulin molecules specific for at least one antigen derived from a component of the immune system, specifically an anti-CD3 antibody. The invention further provides methods kits and uses of the combined compositions of the invention for immune-modulation and thereby for the treatment of immune-related disorders. In a preferred embodiment, anti-CD3 antibody (OKT3) is orally administered in combination with β-glucosylceramide (also known as glycocerebroside) in an animal model of type 2 diabetes.

The invention provides a manufacturing method of a ceramide generation accelerator and / or a glucosylceramide generation accelerator, wherein Candida microorganisms are cultured in a culture medium containing beam dregs and saccharides, and the ceramide generation accelerator and / or the glucosylceramide generation accelerator are / is obtained from an obtained supernatant. According to the manufacturing method disclosed by the invention, by utilization of specific microorganisms and byproducts, namely the bean dregs, of the food processing industry and the like as a main raw material of the culture medium, the ceramide generation accelerator and / or the glucosylceramide generation accelerator can be acquired at low cost and high efficiency.

To produce a glucosylceramide composition suitable for a functional food or a medicinal product, having stable quality, and cleared of contaminants such as sterol glycosides. An objective is to produce a glucosylceramide composition at low cost from a raw material which is safe, has been eaten by human beings, and is readily available. A glucosylceramide-containing composition is produced by extraction from a raw material of a yeast residue in an organic solvent, such as an alcohol, the yeast residue being obtained after extraction of yeast extract from Torula yeast or the like.

The invention discloses a method for preparing Eliglustat. The Eliglustat is an effective specific glucosylceramide systhase inhibitor, which can be used for treating type-I Gaucher disease. The invention provides the synthetic method of Eliglustat, which comprises the following steps: 1,4-benzdioxan-6-formaldehyde and a chiral ligand are subjected to an adiastereoselectivity Aldol reaction, and then subjected to a reduction reaction, replacement and a Staudinger reaction, and an amidation reaction to obtain Eliglustat. The method has the advantages of easy acquisition of raw material, simpleoperation, high product yield and purity, and easy industrial large production.

Deoxynojirimycin and deoxygalactonojirimycin derivatives according to the present invention are N-alkylated D-galacto, D-gluco- or L-ido-deoxynojirimycin with a linear methyloxypentyl group bearing various sidegroups and a non-fused bicyclic aromatic group (“X”) on the methyloxy-carbon. These compounds display an increased inhibitory potency towards GCS, and / or an increased inhibitory potency towards GBA2, and / or a decreased inhibitory potency towards GBA1, relative to known deoxynojirimycin derivatives of the same (D-gluco, L-ido or D-galacto) configuration. Therefore, compounds of the present invention are effective in the treatment of diseases which are associated with an irregular level of cytosolic or lysosomal glucosylceramide and / or higher glycosphingolipids, such as a lysosomal storage disorder, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Sandhoff disease, GM1 gangliosidosis, Sialidosis, Niemann Pick disease type C and AMRF, or a symptom of one of the diseases collectively classed as metabolic syndrome, such as obesity, insulin resistance, hyperlipidemia, hypercholesterolemia, polycystic kidney disease, type II diabetes and chronic inflammation, or a neurodenegerative disorder, such as Parkinson disease or Lewy-body dementia.

The invention provides a preparation method of a promoter for producing ceramide and / or glucosylceramide, wherein debaryomyces microbes are cultured in a culture medium containing bean dregs and saccharides, and the promoter for producing ceramide and / or glucosylceramide is obtained from the supernatant. According to the preparation method of the invention, special microbes are used, and bean dregs which are by products in food processing industry are used as a main raw material of the culture medium; therefore the promoter for producing ceramide and / or glucosylceramide is obtained with low cost and high efficiency.

The invention provides a manufacturing method of a ceramide production accelerating agent and / or a glucosylceramide ceramide production accelerating agent. The method comprises the following steps of: culturing a microorganism of Leuconstoc in a culture medium containing bean dregs and saccharides, and obtaining the ceramide production accelerating agent and / or the glucosylceramide ceramide production accelerating agent from supernate. According to the manufacturing method provided by the invention, the ceramide production accelerating agent and / or the glucosylceramide ceramide production accelerating agent can be efficiently obtained at low cost through utilizing an easily obtained substance as the culture medium and utilizing a specific microorganism.

Provided are a method for efficiently producing free ceramide (especially human-type free ceramide) and the like. The extract obtained from chestnut bark contains relatively abundant free ceramides and glucosylceramides, which is useful. In addition, chestnut bark acetone extract has ultraviolet absorption and ultraviolet wavelength conversion actions, which is useful.

The invention provides a manufacturing method of a ceramide production accelerating agent and / or a glucosylceramide ceramide production accelerating agent. The method comprises the following steps of: culturing a microorganism of Leuconstoc in a culture medium containing bean dregs and saccharides, and obtaining the ceramide production accelerating agent and / or the glucosylceramide ceramide production accelerating agent from supernate. According to the manufacturing method provided by the invention, the ceramide production accelerating agent and / or the glucosylceramide ceramide production accelerating agent can be efficiently obtained at low cost through utilizing an easily obtained substance as the culture medium and utilizing a specific microorganism.

The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.

The invention provides a PED (Porcine Epedemic Diarrhea) inactivated vaccine and a preparation method thereof and relates to the field of biopharmacy. The PED inactivated vaccine comprises inactivated PEDV (Porcine Epedemic Diarrhea Virus), and is characterized in that the PED inactivated vaccine comprises 0.05-10 mg / mL Beta-glucosylceramide, 0.1-21 mg / mL monophosphoryl lipid A, 1.5-125 mg / mL muramyl dipeptide and 0.7-4.5 mg / mL Beta-glucan. According to the ingredients of the PED inactivated vaccine, Beta-glucosylceramide, monophosphoryl phosphoryl lipid A, muramyl dipeptide and Beta-glucan have the synergistic effect, the immune response of animals to antigens in the vaccine is significantly improved, the immune window phase is shortened, the antibody production duration of the animal body is obviously prolonged, the serum antibody level is improved, and the level of total intestinal mucosa secretory antibodies (the total SIgA) is improved.

The invention provides means and methods for detecting a glycosylated metabolite in a sample comprising adding to the sample a compound comprising a labelled glycosyl group coupled via an O-glycosidic bond to an aglycon with a specific structural formula wherein the glycosyl group comprises at least one isotope and / or a side chain being a label for detection, and wherein the sample is screened for the presence of a glycosylated metabolite with the glycosyl group other than a glucosylceramide. The invention further provides a method of treating a disorder caused by accumulation of a glycosylated metabolite other than glucosylceramide in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a glucosylceramide synthase (GCS) inhibitor.

The invention relates to a method for preparing D-glucosylceramide by using a soy sauce filter residue, and is characterized in that the method comprises the following steps: activating strains: A, respectively inoculating 100 mL of an activation culture medium with an sphingomonas strain and a yarrowia lipolytica strain; B, carrying out aerobic fermentation culture of the sphingomonas strain activated culture liquid P and the yarrowia lipolytica strain activated culture liquid Q obtained in the step A for 36-72 h, to obtain a composite strain fermentation liquid; C, mixing the composite strain fermentation liquid with the soy sauce filter residue, adding the mixture into a compound fermentation tank, carrying out static culture, and culturing for 48-96 h at the temperature of 25-30 DEG C, to obtain a strain cell-rich filter residue; and carrying out high pressure homogenization for 2 times, to obtain a wall-broken cell homogenate; and D, mixing the wall-broken cell homogenate with an ethanol solution, filtering to obtain a precipitate, and thus obtaining a D-glucosylceramide extract. Through rational use of the soy sauce filter residue, the waste can be turned into treasure, soy sauce industries are facilitated to improve economic benefits, and the resource utilization of the soy sauce filter residue and the development of high-value by-products are greatly improved.